Nov. 17 at 1:03 PM
$INDP Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit
https://www.globenewswire.com/news-release/2025/11/17/3189055/0/en/Indaptus-Therapeutics-Chief-Scientific-Officer-Dr-Michael-Newman-to-Present-at-the-Donor-Selection-Cell-Source-Summit.html
Dr. Newman stated, “Allogeneic therapies, which rely on donor-derived immune cells to create ‘off-the-shelf’ cancer treatments, face a major hurdle when it comes to achieving consistent potency across donor sources. Our preclinical data show that Decoy bacteria can activate or induce the production of key immune cell types—such as NK cells, gamma-delta T cells, and M1 macrophages—that are also central to the success of allogeneic immunotherapies. This suggests that Decoy bacteria may have potential as an enabling tool to enhance the potency and reproducibility of donor-derived cell therapies.”
